Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1912 • ACR Convergence 2023
Impact of Pharmacist-Led Specialty Medication Management Service on Time-to-Dispense for Specialty Rheumatologic Medications in a University Health System
Khashayar Ahmadmehrabi¹, Navin Ravishankar², Diana Mekhiel³ and Zineb Aouhab³, ¹Loyola University Medical Center, Oak Park, IL, ²Indiana University Health, Indianapolis, IN, ³Loyola University Medical Center, Maywood, IL
Background/Purpose: Given the progressive joint damage and physical disability associated with uncontrolled Rheumatoid arthritis (RA), a treat-to target-strategy through the early utilization of disease-modifying antirheumatic…
Abstract Number: 2101 • ACR Convergence 2023
Diagnosis of Mental Disorder Complicated by Rheumatoid Arthritis: A Study of the Validity of a Psychiatrist’s Diagnosis and Questionnaire Method
Yusuke Miwa¹, Yuko Miwa-mitamura², Hiroi Tomioka³ and Michio Hosaka⁴, ¹Division of Rheumatology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan, ²Department of Nursing, Showa University School of Nursing and Rehabilitation Sciences, Tokyo, Japan, ³Department of Psychiatry, School of Medicine, Showa University, Yokohama, Japan, ⁴Department of psychosomatic medicine, Katsuyama Clinic, Fujikawaguchiko, Japan
Background/Purpose: It has been reported that about 15% of patients with rheumatoid arthritis (RA) have depression, and most of these studies have used questionnaire methods.…
Abstract Number: 2118 • ACR Convergence 2023
New Onset Disability in Rheumatoid Arthritis Is an Underrecognized Cardiovascular Risk Factor: A Retrospective Cohort Study Using the CorEvitas Registry
Robert Spandorfer¹, Kevin Kane², George Reed², Dimitrios Pappas², Joel Kremer², Jeffrey Curtis³ and Iris Navarro-Millán⁴, ¹Hospital for Special Surgery, Brooklyn, NY, ²CorEvitas, LLC, Waltham, MA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Weill Cornell Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Cardiovascular disease (CVD) is the most common cause of death among patients with RA. Prior research found a higher rate of CVD events associated…
Abstract Number: 2134 • ACR Convergence 2023
Autoantibodies to Joint-related Proteins Predict Remission with High Specificity in New Onset RA
Monica Leu Agelii¹, Outi Sareila², Erik Lönnblom², Kristina Forslind³, Maria Andersson³, Alf Kastbom⁴, Christopher Sjöwall⁵, Lennart Jacobsson⁶, Jan Kihlberg⁷, Rikard Holmdahl², Ingiäld Hafström² and Inger Gjertsson⁸, ¹Gothenburg University, Goteborg, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³FoU Spenshult, Halmstad, Sweden, ⁴Linköping University, Linköping, Sweden, ⁵Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, ⁶University of Gothenburg, Malmö, Sweden, ⁷Uppsala University, Uppsala, Sweden, ⁸Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: One of the major challenges in the management of rheumatoid arthritis (RA) is to determine individual treatment and predict the prognosis. On a group…
Abstract Number: 2150 • ACR Convergence 2023
Novel Biologic IRL201805 Inhibits Osteoclastogenesis in Monocytic Cells from RA Patients
Yuriko Yamamura¹, Valerie Corrigall², Lara Ravanetti³, Jorge De Alba³, Roly Foulkes⁴, Paul Eggleton⁵ and Carl Goodyear⁶, ¹School of Infection & Immunity, University of Glasgow, Glasgow, United Kingdom, ²Revolo Biotherapeutics, Tadworth, United Kingdom, ³Revolo Biotherapeutics, London, United Kingdom, ⁴Revolo Biotherapeutics, Slough, United Kingdom, ⁵Revolo Biotherapeutics, Exeter, United Kingdom, ⁶University of Glasgow, Glasgow, United Kingdom
Background/Purpose: In Rheumatoid arthritis (RA), osteoclasts derived from CD14+ Monocytes are associated with a risk of progressive bone and joint destruction, which fundamentally impacts quality-of-life.…
Abstract Number: 2167 • ACR Convergence 2023
24-week, Post-Marketing Surveillance Analysis of Upadacitinib in Japanese Patients with Rheumatoid Arthritis (Encore1)
Tatsuya Atsumi¹, Nami Okamoto², Nobunori Takahashi³, Naoto Tamura⁴, Atsuo Nakajima⁵, Ayako Nakajima⁶, Takao Fujii⁷, Hiroaki Matsuno⁸, Takeshi Kawaberi⁹, Naomi Sunaga⁹, Yuki Tsujita¹⁰, Sumi Chonan⁹, Masataka Kuwana¹¹ and Michiaki Takagi¹², ¹Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, ²Department of Paediatrics, Osaka Rosai Hospital, Sakai-city, Japan, ³Department of Orthopedic Surgery, Aichi Medical University, Nagakute, Japan, ⁴Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan, ⁵Ueno Dialysis Clinic, Taito-ku, Japan, ⁶Center for Rheumatic Diseases, Mie University Hospital, Tsu, Japan, ⁷Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan, ⁸Matsuno Clinic for Rheumatic Diseases, Toyama City, Japan, ⁹AbbVie GK, Minato-ku, Japan, ¹⁰Abbvie GK, Minato City Tokyo, Japan, ¹¹Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ¹²Department of Orthopaedic Surgery, Yamagata University Faculty of Medicine, Yamagata, Japan
Background/Purpose: Upadacitinib (UPA) was approved in 2020 in Japan for the treatment of "Rheumatoid arthritis (RA) patients with inadequate response to conventional therapy, including inhibition…
Abstract Number: 2435 • ACR Convergence 2023
Deciphering Rheumatoid Arthritis Disease Activity-Associated Gene Signatures and Cell Subsets Through Single Cell Transcriptomics
Marie Binvignat¹, Brenda Miao², Camilla Wibrand³, Monica Yang⁴, Dmitry Rychkov⁵, Emily Flynn⁴, Umair Khan⁴, Joanne Nititham⁶, Alex Carvidi⁴, Melissa Krueger⁴, Erene Niemi⁴, Yang Sun⁴, Gabriella Fragiadakis⁴, David Klatzmann¹, Jeremie SELLAM⁷, Encarnita Mariotti-Ferrandiz¹, Andrew Gross⁴, Chun Jimmie Ye⁴, Atul Butte⁴, Lindsey Criswell⁶, Mary Nakamura⁸ and Marina Sirota⁵, ¹Sorbonne Université, Paris, France, ²University of California San Francisco, Fremont, CA, ³Aarhus University, Aarhus, Denmark, and University of California San Francisco, San Francisco, CA, ⁴University of California San Francisco, San Francisco, CA, ⁵Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA, ⁶NIH/NHGRI, Bethesda, MD, ⁷Sorbonne Université APHP, Paris, France, ⁸UCSF/SFVAHCS, San Francisco, CA
Background/Purpose: Single cell transcriptional profiling (scRNA-Seq) is valuable in identifying gene signatures and cell subpopulations associated with rheumatoid arthritis (RA). However prior studies have often…
Abstract Number: 2509 • ACR Convergence 2023
Risk Factors and Mortality of Immune Checkpoint Inhibitor-Induced Flares of Pre-Existing Rheumatoid Arthritis: An Analysis Accounting for Competing Risk of Death and Immortal Time Bias
Kaitlin McCarter¹, Senada Arabelovic¹, Taylor Wolfgang¹, Xiaosong Wang¹, Kazuki Yoshida¹, Grace Qian¹, Emily Kowalski¹, Kathleen Vanni¹, Nicole LeBoeuf¹, Elizabeth Buchbinder², Lydia Gedmintas¹, Lindsey MacFarlane¹, Deepak Rao¹, Nancy Shadick³, Ellen Gravallese⁴ and Jeffrey Sparks⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Dana-Farber Cancer Institute, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Immune checkpoint inhibitors (ICI) stimulate the immune system to treat cancer but may cause flares of pre-existing immune-mediated inflammatory diseases. Risk factors for ICI-induced…
Abstract Number: PP06 • ACR Convergence 2023
Dana’s Data Dashboard: Applying a Familiar Framework for Efficient and Effective Health Management
Dana Guglielmo, Los Angeles, CA
Background/Purpose: As a researcher and data analyst, I enjoy the meticulous attention to detail that my work requires. I love the process of collecting, analyzing,…
Abstract Number: 0016 • ACR Convergence 2023
Role of TP53 in Inflammatory Reprogramming of Rheumatoid Arthritis Synovial Fibroblasts
Anil Singh and Salahuddin Ahmed, Washington State university, Spokane, WA
Background/Purpose: TP53, a tumor-suppressor protein known as the guardian of the genome, plays a critical role in regulating genomic stability and cellular function. When TP53…
Abstract Number: 0079 • ACR Convergence 2023
CD4 T Cell Repertoire Features in RA Patients with High-risk HLA-DRB1 Alleles
Amit Lakhanpal¹, Kazuyoshi Ishigaki², Anvita Singaraju¹, Alejandro Kochen³, Miriam Fein¹, Soumya Raychaudhuri⁴ and Laura Donlin¹, ¹Hospital for Special Surgery, New York, NY, ²RIKEN, Tokyo, Japan, ³Yale School of Medicine, New Haven, CT, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: A role for CD4 T cells in RA pathology is supported by the effectiveness of T cell therapies, genetic studies implicating T cell gene…
Abstract Number: 0217 • ACR Convergence 2023
Safety and Efficacy of Tixagevimab/Cilgavimab (Evusheld) in Autoimmune Inflammatory Rheumatic Disease Patients – a Prospective Multicenter Open-label Study
Tali Eviatar¹, Victoria Furer², Ilana Kaufman³, David levartovsky², Ofir Elalouf², Devy Zisman⁴, Tal Gazitt⁵, Amir Haddad⁴, Muna Elias⁶, Joy Feld⁷, Alexandra Balbir-Gurman⁸, Yolanda Braun Moscovici⁹, Sara Pel¹⁰, sharon Nevo¹¹, Daphna Paran² and Ori Elkayam², ¹Tel Aviv Sourasky Medical center, Ramat Gan, Israel, ²Tel Aviv Medical Center, Tel Aviv, Israel, ³Tel Aviv Medical Center, Petah-Tikva, Israel, ⁴Carmel Medical Center, Haifa, Israel, ⁵Carmel Hospital, Haifa, Israel, ⁶rheumatology unit, Haifa, Israel, ⁷Carmel and Zvulun Medical Centre, Haifa, Israel, ⁸Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, ⁹Rambam Heath Care Campus, Haifa, Israel, ¹⁰Tel Aviv Medical Center, Modiin, Israel, ¹¹Tel Aviv Sourasky Medical Center, Givataim, Israel
Background/Purpose: Autoimmune inflammatory rheumatic disease (AIIRD) patients treated with rituximab (RTX) are at risk for severe COVID19 infection, and a blunted humoral response to SARS-CoV-2…
Abstract Number: 0383 • ACR Convergence 2023
Identification of Contributing Factors to Difficult-to-Treat Rheumatoid Arthritis (D2T RA) in a Cohort of 972 Patients Using a Natural Language Processing (NLP) Approach
Hugo BERGIER¹, Thibaut Fabacher², Nathanaël Sedmak², Erik Sauleau² and Jacques-Eric Gottenberg³, ¹Hautepierre Hospital, Strasbourg, France, ²Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ³Rheumatology Department, Strasbourg University Hospital, Strasbourg, France
Background/Purpose: Natural Language Processing (NLP), an interdisciplinary field combining artificial intelligence and language science, has gained significant interest in the medical domain for automated collection…
Abstract Number: 0399 • ACR Convergence 2023
Differential Synovial Tissue Enrichment of Oxylipins and Their Mediators Across Rheumatoid Arthritis Trajectory
Simone Perniola¹, Jessica Murillo-Saich², Barbara Tolusso³, Clara Di Mario³, Marco Gessi⁴, Dario Bruno⁵, Luca Petricca⁶, Maria Rita Gigante⁶, Elisa Gremese⁵, Monica Guma⁷ and Stefano Alivernini⁸, ¹Division of Clinical Immunology – Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ²Department of Medicine, University of California San Diego, La Jolla, CA, ³Immunology Research Core Facility – Gemelli Science and Technology Park (GSTeP) - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁴Division of Pathology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁵Division of Rheumatology, Institute of Rheumatology and Affine Sciences, School of Medicine, Catholic University of the Sacred Heart, Roma, Italy, ⁶Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁷University of California San Diego, La Jolla, CA, ⁸Immunology Research Core Facility, Gemelli Science and Technology Park, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy
Background/Purpose: Synovial membrane represents the target tissue of Rheumatoid Arthritis (RA) inflammation. Our study aimed to perform a comprehensive quantification of oxylipins and their precursors…
Abstract Number: 0416 • ACR Convergence 2023
Association Between Sleep Disorders and Rheumatoid Arthritis: A Population-based Cohort Study
Rakesh Kumar¹, Edward Lovering¹, Chanakya Kodishala², Sara Achenbach³, Diego Carvalho¹, Cynthia Crowson¹, John Davis¹ and Elena Myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Rochester Minnesota, Rochester, MN, ³Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: Some sleep disorders (SD) are more prevalent in patients with chronic inflammatory diseases, such as Rheumatoid Arthritis (RA). However, most of the research has…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.